Related Experiment Video
Updated: Jun 8, 2026
12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Do general practitioners recognize mild cognitive impairment in their patients?
H Kaduszkiewicz1, T Zimmermann, H Van den Bussche
1Department of Primary Medical Care, Center for Psychosocial Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. kaduszki@uke.uni-hamburg.de
The Journal of Nutrition, Health & Aging
|October 6, 2010
Summary
General Practitioners (GPs) have a low sensitivity (11-12%) in recognizing mild cognitive impairment (MCI) in primary care. Improved tools and training are needed for better detection of this dementia risk factor.
Area of Science:
- Geriatrics
- Neurology
- Primary Care Medicine
Background:
- Mild cognitive impairment (MCI) is a significant risk factor for dementia.
- General Practitioners (GPs) are well-positioned for early MCI detection due to regular patient contact.
- The current ability of GPs to recognize MCI in primary care settings requires investigation.
Purpose of the Study:
- To evaluate the accuracy of General Practitioners (GPs) in identifying patients with mild cognitive impairment (MCI) within their practice population.
- To assess the sensitivity and specificity of GPs' clinical judgment in MCI recognition.
Main Methods:
- A cross-sectional study was conducted using a primary care chart registry sample.
- 3,242 non-demented patients aged 75-89 years were included.
- GPs used the Global Deterioration Scale (GDS); MCI cases were defined by a gold standard using psychometric data from trained interviewers.
Main Results:
- GPs demonstrated very low sensitivity (11-12%) but high specificity (93-94%) in detecting MCI.
- False negative assignments were more common in patients with higher education levels.
- False positive assignments increased with patient comorbidity; detection improved when memory or multiple domains were affected.
Conclusions:
- GPs recognize MCI in a limited number of cases based solely on clinical impression.
- There is a need for improved, validated, and standardized tools for MCI detection in primary care.
- Focus should shift towards case-finding approaches and broader cognitive assessments beyond memory.
More Related Videos
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Cognitive Development During Adulthood
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.